Schizophrenia Clinical Trial
Official title:
Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation
Background:
The present study aims to identify the mechanisms underlying the deficit in facial emotion
recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus,
reveal a distinction between the two disorders. Indeed, despite the clinical overlap between
the two syndromes, some of the symptoms appear to be specific to only one of them. In
particular, the disturbance of visual functions is specifically observed in the 22q11.2DS.
Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS
are likely accounted by different cognitive impairments. Investigating which mechanisms are
disturbed would allow a specialized support for patients.
Our main hypothesis is that the deficit in facial emotion recognition is more related to
visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in
two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy
subjects) using an experimental paradigm based on electroencephalography (EEG).
A second aim of this study is to determine whether the severity of the two disorders'
symptoms is correlated with the cerebral response to facial expressions. To answer this
question, a set of clinical and neuropsychological tests will be conducted for each patient.
Methods:
This study will be conducted using visual steady-state visual evoked potentials (SSVEPs).
Visual SSVEPs are periodic neural electrophysiological activities that arise in response to
fast periodic visual stimulation (FPVS). They will be recorded in response to the periodic
presentation of faces, according to an oddball paradigm. While pictures of faces will appear
at a 6 Hz rate, only 1 out of 5 will display an emotion, corresponding to a 1.2 Hz oddball
frequency. Different emotions will be tested (happiness, sadness, anger, fear and disgust),
displayed with different intensities (20%, 60%, 100%). SSVEPs at 6 Hz will reflect general
visual mechanisms (in response to a mixture of low-level (i.e., contrast coding) and
high-level (i.e., face detection) processes). Importantly, SSVEPs at 1.2 Hz will index the
visual mechanisms specifically involved in facial expression perception and their sensitivity
to emotion intensity. Both measures will help determine the underlying brain topographies.
Alongside, clinical and neuropsychological tests will be conducted. While the clinical tests
will evaluate the severity of the symptoms, the neuropsychological tests will assess
different features such as attention, memory, verbal and visuo-spatial abilities. The
patients' scores will be linked with their cerebral activity in response to facial
expressions.
Outcomes:
To better understand the impairment of facial emotion recognition in schizophrenia and
22q11.2DS and to improve its care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |